Blueprint Medicines Corporation ( BPMC ) NASDAQ Global Select

Cena: 129.46 ( 0.14% )

Aktualizacja 07-18 22:00
NASDAQ Global Select
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Blueprint Medicines Corporation, firma zajmująca się terapią precyzyjną, opracowuje leki na zdefiniowane genomicznie nowotwory i zaburzenia krwi w Stanach Zjednoczonych i na arenie międzynarodowej. Firma rozwija ajvakit w leczeniu ogólnoustrojowej mastocytozy (SM) i nowotworów zrębowych przewodu pokarmowego; BLU-263, dostępny doustnie, silny i zestaw zestawów do leczenia nieodvanced SM i innych zaburzeń komórek tucznych; oraz fisogatynib, dostępny doustnie i silny inhibitor do leczenia raka wątrobowokomórkowego. Rozwija się również Gavreto w leczeniu nieruchomego raka płuc z dodatnim fuzją RET, zmienionym nowotworami litych, rdzenia rdzenia tarczycy i innych guzów litych; BLU-701 i Blu-945 do leczenia raka płucnego napędzanego naskórkowego czynnika wzrostu opartego na mapilu (NSCLC); i Blu-451 w leczeniu NSCLC u pacjentów z mutacjami eksonu 20 insercji receptora czynnika wzrostu (EGFR). Ponadto firma opracowuje Blu-782, do leczenia Fibrodysplasia Ossificans postępującego; BLU-222 w leczeniu pacjentów z nieprawidłowymi nowotworami; i Blu-852 do leczenia zaawansowanych nowotworów. Ma umowy o współpracy i licencji z Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; Cstone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd i Hoffmann-La Roche Inc.; oraz Zai Lab (Szanghaj) Co., Ltd. Firma była wcześniej znana jako Hoyle Pharmaceuticals, Inc. i zmieniła nazwę na Blueprint Medicines Corporation w czerwcu 2011 r. Blueprint Medicines Corporation został zarejestrowany w 2008 roku i ma siedzibę w Cambridge, Massachusetts.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 638
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 98.1013
Ilość akcji: Brak danych
Debiut giełdowy: 2015-04-30
WWW: https://www.blueprintmedicines.com
CEO: Ms. Kathryn Haviland M.B.A.
Adres: 45 Sidney Street
Siedziba: 02139 Cambridge
ISIN: US09627Y1091
Wskaźniki finansowe
Kapitalizacja (USD) 8 360 811 612
Aktywa: 1 199 649 000
Cena: 129.46
Wskaźnik Altman Z-Score: 2.0
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: -51.6
Ilość akcji w obrocie: 98%
Średni wolumen: 3 287 638
Ilość akcji 64 582 200
Wskaźniki finansowe
Przychody TTM 434 414 000
Zobowiązania: 886 501 000
Przedział 52 tyg.: 73.04 - 129.55
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -2.5
P/E branży: 28.3
Beta: 0.59
Raport okresowy: 2025-07-31
WWW: https://www.blueprintmedicines.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Percy H. Carter M.B.A., Ph.D. Chief Scientific Officer 986 860 1971
Mr. Michael Landsittel Chief Financial Officer 881 863 1972
Ms. Tracey L. McCain Esq. Executive Vice President, Chief Legal & Compliance Officer and Secretary 764 901 1968
Mr. Alexis A. Borisy A.M. Co-Founder & Director 50 000 1972
Dr. Christopher K. Murray Ph.D. Chief Technical Operations & Quality Officer 338 367 1963
Ms. Kathryn Haviland President, Chief Executive Officer & Director 1 515 120 1976
Ms. Christina Rossi M.B.A. Chief Operating Officer 1 102 518 1976
Dr. Fouad Namouni M.D. President of Research & Development 1 098 087 1969
Jenna Cohen Senior Director & Head of Investor Relations 0 0
Ms. Ariel Hurley Senior Vice President, Finance & Principal Accounting Officer 0 1974
Lista ETF z ekspozycją na akcje Blueprint Medicines Corporation
Symbol ETF Ilość akcji Wartość
VB 1 578 244 202 299 315
VBK 885 232 113 469 037
VTWO 325 490 41 721 308
VHT 199 056 25 514 998
VTWG 56 728 7 271 395
FDG 27 379 1 603 453
JHMM 17 864 1 791 937
ESGV 13 705 1 756 706
GSSC 5 183 666 274
VTHR 4 980 638 336
GUSA 2 129 273 682
GDOC 1 301 167 243
V3AB.L 833 80 912
V3AL.L 833 106 773
V3AA.L 833 106 773
NSCS 286 32 183
WBIO.L 164 21 034
WDNA.L 164 21 034
Wiadomości dla Blueprint Medicines Corporation
Tytuł Treść Źródło Aktualizacja Link
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025. zacks.com 2025-05-02 17:25:33 Czytaj oryginał (ang.)
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communications Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating Officer Conference Call Participants Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Yee - Jefferies Colleen Kusy - Baird Derek Archila - Wells Fargo Brian Cheng - JPMorgan Reni Benjamin - Citizens Ami Fadia - Needham David Dai - UBS Judah Frommer - Morgan Stanley Sudan Loganathan - Stephens Operator Good morning. My name is Angela and I'll be your conference operator today. seekingalpha.com 2025-05-01 18:01:43 Czytaj oryginał (ang.)
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago. zacks.com 2025-05-01 13:26:10 Czytaj oryginał (ang.)
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass. , May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. prnewswire.com 2025-05-01 11:00:00 Czytaj oryginał (ang.)
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. prnewswire.com 2025-04-25 12:00:00 Czytaj oryginał (ang.)
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy? Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-24 15:08:54 Czytaj oryginał (ang.)
Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth Blueprint Medicines' focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other promising candidates (BLU-808 and Elenestinib) for mast cell disorders and genetically driven cancers. Their recent data seems to reinforce Ayvakit's long-term safety, efficacy, and potential bone health benefits in systemic mastocytosis patients. seekingalpha.com 2025-04-07 09:37:02 Czytaj oryginał (ang.)
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference CAMBRIDGE, Mass. , March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. prnewswire.com 2025-03-31 12:00:00 Czytaj oryginał (ang.)
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress -- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy -- -- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course --  -- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor -- CAMBRIDGE, Mass. , Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. prnewswire.com 2025-02-28 10:00:00 Czytaj oryginał (ang.)
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement. zacks.com 2025-02-14 17:01:14 Czytaj oryginał (ang.)
Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Cassie Saitow - Director, Investor Relations Kate Haviland - President and Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christina Rossi - Chief Operating Officer Conference Call Participants Brad Canino - Stifel Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Brian Cheng - J.P. Morgan Derek Archila - Wells Fargo Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Ulz - Morgan Stanley David Dai - UBS Reni Benjamin - Citizens JMP Colleen Kusy - Baird Matthew Biegler - Oppenheimer David Nierengarten - Wedbush Securities Operator Good morning. seekingalpha.com 2025-02-13 13:32:30 Czytaj oryginał (ang.)
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago. zacks.com 2025-02-13 11:25:17 Czytaj oryginał (ang.)
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results -- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint -- -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 -- -- AYVAKIT 3-year safety and efficacy results in ISM and BLU-808 healthy volunteer data among 14 total abstracts accepted for presentation at 2025 AAAAI / WAO Joint Congress -- CAMBRIDGE, Mass. , Feb. 13, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2024 and provided financial guidance. prnewswire.com 2025-02-13 09:00:00 Czytaj oryginał (ang.)
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-02-06 13:05:47 Czytaj oryginał (ang.)
Should You Buy Blueprint Medicines (BPMC) After Golden Cross? After reaching an important support level, Blueprint Medicines Corporation (BPMC) could be a good stock pick from a technical perspective. BPMC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. zacks.com 2025-02-06 12:56:28 Czytaj oryginał (ang.)
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 CAMBRIDGE, Mass. , Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. prnewswire.com 2025-02-05 10:00:00 Czytaj oryginał (ang.)
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress. zacks.com 2025-01-14 13:16:11 Czytaj oryginał (ang.)
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector. zacks.com 2025-01-14 13:06:12 Czytaj oryginał (ang.)
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar? Blueprint Medicines (BPMC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com 2025-01-14 07:46:09 Czytaj oryginał (ang.)
Blueprint Medicines price target lowered by $11 at Wedbush, here's why Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%) https://thefly.com 2025-01-13 10:44:32 Czytaj oryginał (ang.)
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth -- Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates --  -- Expect to achieve $2 billion in AYVAKIT revenue by 2030 -- -- BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study -- -- Kate Haviland, CEO, to present at J.P. Morgan conference on Monday, January 13 at 9:00 a.m. prnewswire.com 2025-01-12 18:00:00 Czytaj oryginał (ang.)
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. prnewswire.com 2024-12-18 10:00:00 Czytaj oryginał (ang.)
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting -- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM -- -- Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT --  CAMBRIDGE, Mass. , Dec. 7, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the company's ongoing partnership with the SM community to redefine the future of patient care – from improving diagnostic rates to raising the bar on treatment outcomes. prnewswire.com 2024-12-07 14:30:00 Czytaj oryginał (ang.)
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-11-29 14:37:53 Czytaj oryginał (ang.)
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential. seekingalpha.com 2024-11-15 19:26:36 Czytaj oryginał (ang.)
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells. benzinga.com 2024-11-14 17:18:38 Czytaj oryginał (ang.)
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024. zacks.com 2024-10-31 11:46:19 Czytaj oryginał (ang.)
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Reni Benjamin - Citizens JMP Paul Jeng - Guggenheim Tommie Reerink - Goldman Sachs Derek Archila - Wells Fargo Mike Ulz - Morgan Stanley Ami Fadia - Needham Markus Schweiger - Oppenheimer Peter Lawson - Barclays Laura Prendergast - Raymond James David Lebowitz - Citi Sudan Loganathan - Stephens Operator Good morning. My name is Nadia, and I'll be your conference operator today. seekingalpha.com 2024-10-30 16:29:08 Czytaj oryginał (ang.)
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago. zacks.com 2024-10-30 11:16:30 Czytaj oryginał (ang.)
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance -- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- --  On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance. prnewswire.com 2024-10-30 09:00:00 Czytaj oryginał (ang.)
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector. zacks.com 2024-10-24 14:11:17 Czytaj oryginał (ang.)
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-23 15:07:49 Czytaj oryginał (ang.)
Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock? Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2024-10-21 17:00:19 Czytaj oryginał (ang.)
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 CAMBRIDGE, Mass. , Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. prnewswire.com 2024-10-16 12:00:00 Czytaj oryginał (ang.)
Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-10-15 14:56:10 Czytaj oryginał (ang.)
The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-09-11 15:00:00 Czytaj oryginał (ang.)
Blueprint Medicines to Present at Upcoming Investor Conferences CAMBRIDGE, Mass. , Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. prnewswire.com 2024-09-10 12:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors To Join An Inquiry Into Blueprint Medicines Corporation For Possibly Committing Securities Related Infractions LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-09-09 15:00:00 Czytaj oryginał (ang.)
Blueprint Medicines Corporation May Have Engaged In Securities Fraud And Shareholder Participation In An Investigation Is Encouraged By The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-09-07 15:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Possible Securities Law Violations And Investors Are Urged To Join The Inquiry LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-09-06 15:00:00 Czytaj oryginał (ang.)
Blueprint Medicines Corporation May Have Defrauded Shareholders And The Schall Law Firm Wants Those With Losses To Reach Out LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-09-05 15:00:00 Czytaj oryginał (ang.)